Description

Brd3731 is a high-purity, research-grade bromodomain inhibitor compound widely utilized in epigenetic drug discovery and target validation studies. It offers selective binding to the BRD3 bromodomain, enabling precise modulation of transcriptional regulation pathways critical in oncology and inflammatory disease research. This compound is essential for pharmaceutical R&D laboratories, academic research institutions, and contract research organizations (CROs) conducting mechanistic studies, structure–activity relationship (SAR) profiling, and preclinical candidate optimization. Brd3731 CAS NO 2056262-08-7 is supplied under stringent quality controls to ensure batch-to-batch consistency and biological reproducibility.

Application

• Target validation and functional screening in BRD3/BRD4-dependent cancer models (e.g., AML, multiple myeloma, NUT midline carcinoma)
• Chemical probe development for epigenetic mechanism-of-action studies
• Co-crystallization and structural biology applications to characterize bromodomain–ligand interactions
• In vitro pharmacological profiling including IC50, Kd, and cellular thermal shift assay (CETSA) support
• Lead optimization campaigns requiring high-fidelity reference standards for SAR analysis
• Development of PROTACs and molecular glues targeting bromodomain-containing proteins
• Quality control reference material for analytical method validation (HPLC, LC-MS)
• High-content phenotypic screening in primary human cell assays assessing chromatin remodeling effects

Basic Information

Product Name	Brd3731
CAS No.	2056262-08-7
Molecular Formula	C22H18BrN5O2
Molecular Weight	464.32 g/mol
Synonyms	BRD3731; N-(4-(4-Bromophenyl)-2-oxo-1,2-dihydropyridin-1-yl)-2-(methylamino)acetamide; BRD-3731; BRD 3731; 2056262-08-7; Bromodomain Inhibitor BRD3731; N-[4-(4-Bromophenyl)-2-oxo-1,2-dihydropyridin-1-yl]-2-(methylamino)acetamide; BRD3-selective probe
EINECS	Contact for details

Quality Control

Our products undergo rigorous quality testing to ensure compliance with industry standards. Each batch of Brd3731 is fully characterized by HPLC, LC-MS, 1H NMR, and elemental analysis to confirm identity, purity (>99.0%), and structural integrity. Certificates of Analysis (COA) are available upon request and include full chromatographic traces, spectral data, residual solvent profiles, and heavy metal testing per ICH Q3D guidelines. The compound is manufactured under ISO 9001-certified processes and complies with REACH and applicable FDA cGMP expectations for research-use-only chemical intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store at 2–8 °C under inert atmosphere (argon or nitrogen) to prevent degradation. Due to its hygroscopic nature, maintain low-humidity conditions (<30% RH) and minimize exposure to ambient air during handling. Avoid repeated freeze-thaw cycles.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (LC-MS)	m/z 464.1 [M+H]+ (calcd. 464.07), retention time matches reference standard
Assay (HPLC)	≥99.0%
Related Substances (HPLC)	Any single impurity ≤0.3%; Total impurities ≤1.0%
Residual Solvents (GC)	MeOH ≤3000 ppm; DCM ≤600 ppm; Acetone ≤5000 ppm
Water (Karl Fischer)	≤0.5%
Heavy Metals (ICH Q3D)	≤10 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.